Reactome | Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR ty...

Schema > Summation > Entries

created	[InstanceEdit:1181168] Orlic-Milacic, Marija, 2011-01-28
dbId	1181169
displayName	Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR ty...
literatureReference	[LiteratureReference:1169414] Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity [LiteratureReference:1181162] ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
schemaClass	Summation
text	Gefitinib (ZD1839, Iressa) is a low-molecular-weight EGFR tyrosine kinase inhibitor (TKI) from the anilinoquinazoline class of TKIs, developed by AstraZeneca Pharmaceuticals. Gefitinib selectively inhibits EGFR-stimulated tumor cell growth and blocks EGFR autophosphorylation in tumor cells by competitive inhibition of ATP binding to kinase domain of EGFR (Wakeling et al. 2002, Yun et al. 2007).

(summation)

Cite Us!